Evidence map›Paper›PMID 42832264›Full record

ArticleeLife2026

A high-throughput assay for the measurement of Ca

Stijn Robben, Patricia Davidson, Rita S Rodrigues Ribeiro, Thomas Voets

Abstract read
In one paragraph

Article in eLife, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Stijn RobbenDepartment of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.ORCID https://orcid.org/0009-0003-3372-4443
Patricia Davidson4Dcell, Montreuil, France.ORCID https://orcid.org/0000-0002-3939-3601
Rita S Rodrigues Ribeiro4Dcell, Montreuil, France.
Thomas VoetsDepartment of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.ORCID https://orcid.org/0000-0001-5526-5821

Funding

Fonds Wetenschappelijk Onderzoek G0B7620NFonds Wetenschappelijk Onderzoek G0B9520NHorizon 2020 Framework Programme 10.3030/955643KU Leuven AKUL/19/34Vlaams Instituut voor Biotechnologie
6 · The paper itself

Abstract

Diabetes mellitus is a rapidly growing global health challenge, necessitating the development of more effective anti-diabetic therapies, including drugs that improve insulin release from pancreatic β-cells. Traditional high-throughput screening methods typically rely on 2D β-cell cultures, but such cultures do not mimic the 3D organization and cell-to-cell communication of β-cells in pancreatic islets of Langerhans. Existing 3D β-cell culture models are hindered by high costs, technical complexity, and limited compatibility with high-throughput screening platforms. In this work, we developed an approach for generating 19 homogeneously shaped pancreatic β-cell spheroids in each well of a 96-well plate, using micropatterned polyethylene glycol (PEG)-based hydrogels and murine mouse insulinoma 6 (MIN6) insulinoma cells. The uniform shape and positioning of the individual spheroids enabled the simultaneous, real-time imaging of Ca

Indexed as

CalciumCalcium SignalingHigh-Throughput Screening AssaysInsulinInsulin-Secreting CellsInsulin SecretionSpheroids, CellularAnimalsGlucoseMiceCalciumGlucoseInsulincalcium signalingcell biologyinsulinmousespheroidTRPM3β-cell

Identifiers

PMID42832264
PMCPMC13638198

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.